Onkologie. 2022:16(5):258-262 | DOI: 10.36290/xon.2022.049

Feasibility, dosimetric evaluation and early results of proton radiotherapy in the treatment of bilateral breast cancer

Alexandra Haas, Michal Andrlík, Sarah Falah Abass Alhamami, Andrea Pásztorová

Proton Therapy Center Czech, s. r. o., Praha

Primary synchronously detected bilateral breast cancer (PSBBC) is a relatively rare clinical entity. The adjuvant radiotherapy is a standard part of non-metastatic breast cancer treatment. Despite the fact that this treatment is irreplaceable, it bears the burden of side effects, which may lead to an unacceptable increase of cardiovascular risk and risk of developing secondary malignancy in some patients. Cardiovascular complications have been shown to reduce the survival in breast cancer patients, and therefore efforts should be made to reduce the dose to the heart and cardiac structure as much as possible. Due to its dosimetric advantages, proton radiotherapy offers the possibility to reduce dose to organs at risk while maintaining optimal target volume coverage. This advantage grows with increasing extent and severity of the target volume, among which the synchronously detected bilateral breast cancer clearly belongs. We retrospectively attempted to evaluate the feasibility and safety of using proton radiotherapy in the treatment strategy of synchronously detected bilateral breast cancer.

Keywords: PSBBC (primary synchronous bilateral breast cancer), proton therapy, cardiotoxicity.

Accepted: September 29, 2022; Published: September 29, 2022  Show citation